구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody) Roche / Genentech·PD-L1 141 trials·t½ 27 h |
|---|---|
Overview Program | Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | PD-L1 |
Overview Indication | Carcinoma, Non-Squamous Non-Small Cell Lung |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targets in breast cancer and the most important molecular pathway |
MoA Biomarker | HER2- positive |
PK/PD Half-life | 27 h |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | interstitial lung disease (3% vs 20%; P =  |
Clinical Safety signal | interstitial lung disease (3% vs 20%; P =  |
Clinical Selected reported efficacy | ORR 15.4% |
Clinical Reported ORR | 15.4% |
Clinical Result source | ClinicalTrials.gov NCT04665843 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04665843 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody) Roche / Genentech·PD-L1 141 trials·t½ 27 h |
|---|---|
Overview Program | Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | PD-L1 |
Overview Indication | Carcinoma, Non-Squamous Non-Small Cell Lung |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targets in breast cancer and the most important molecular pathway |
MoA Biomarker | HER2- positive |
PK/PD Half-life | 27 h |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | interstitial lung disease (3% vs 20%; P =  |
Clinical Safety signal | interstitial lung disease (3% vs 20%; P =  |
Clinical Selected reported efficacy | ORR 15.4% |
Clinical Reported ORR | 15.4% |
Clinical Result source | ClinicalTrials.gov NCT04665843 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04665843 |
추천 비교
추천 비교